ZLAB Key Statistics, Chart & Performance
The current stock price of ZLAB is 19.5 USD. In the past month the price decreased by -15.77%. In the past year, price decreased by -30.28%.
ZLAB Latest News, Press Relases and Analysis
ZLAB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About ZLAB
Company Profile
Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-09-28. The firm is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The firm has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
Company Info
ZAI LAB LTD-ADR
Building B, 899 Halei Road, Pudong
Shanghai SHANGHAI 201210 CN
CEO: Samantha (Ying) Du
Employees: 1869
Phone: 862161632588
ZAI LAB LTD-ADR / ZLAB FAQ
Can you describe the business of ZAI LAB LTD-ADR?
Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-09-28. The firm is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The firm has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
Can you provide the latest stock price for ZAI LAB LTD-ADR?
The current stock price of ZLAB is 19.5 USD. The price decreased by -2.26% in the last trading session.
Does ZAI LAB LTD-ADR pay dividends?
ZLAB does not pay a dividend.
How is the ChartMill rating for ZAI LAB LTD-ADR?
ZLAB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about ZAI LAB LTD-ADR (ZLAB) stock?
14 analysts have analysed ZLAB and the average price target is 24.38 USD. This implies a price increase of 25.01% is expected in the next year compared to the current price of 19.5.
What is the Price/Earnings (PE) ratio of ZAI LAB LTD-ADR (ZLAB)?
ZAI LAB LTD-ADR (ZLAB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.88).
ZLAB Technical Analysis
ZLAB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ZLAB. ZLAB has a bad profitability rating. Also its financial health evaluation is rather negative.
ZLAB Financial Highlights
Over the last trailing twelve months ZLAB reported a non-GAAP Earnings per Share(EPS) of -1.88. The EPS increased by 29.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.26% | ||
| ROE | -26.84% | ||
| Debt/Equity | 0.22 |
ZLAB Forecast & Estimates
14 analysts have analysed ZLAB and the average price target is 24.38 USD. This implies a price increase of 25.01% is expected in the next year compared to the current price of 19.5.
For the next year, analysts expect an EPS growth of 43.11% and a revenue growth 41.91% for ZLAB